BioWorld

Oct. 15, 2018

Biopharma money raised: Jan. 1 - Oct. 11, 2018

Money raised by biopharma: 2018 vs. 2017

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

Three quarters in, enthusiasm is high for biopharma deals in 2018, less so for M&As

Dealmaking for the biopharma industry has continued its steady climb through the third quarter of 2018, completing 18 percent more deals that in total are worth 25 percent more than they were this time last year. Read More

Nothing GAINed: Antimicrobial companies see their shares tumble

According to FDA Commissioner Scott Gottlieb, “the emergence of antibiotic resistance threatens the advances we’ve made in medicine.” Read More

Week in Washington

Phase II clinical trials: September 2018

Phase I clinical trials: September 2018

Phase III clinical trials: September 2018

Word on the street

Today's news in brief

BioWorld

BioWorld briefs for Jan 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 15, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...